Search Results - therapeutics+%3e+oncology

135 Results

Sort By:

Synergistic Compositions and Methods Employing Berberine and Enzalutamide for Treatment-Resistant Prostate Cancer (UCLA Case No. 2026-016)

UCLA researchers in the Department of Mechanical and Aerospace Engineering have identified a synergistic therapeutic combination of berberine and enzalutamide for treating treatment-resistant prostate cancer. BACKGROUND: Prostate cancer is one of the leading causes of cancer-related mortality worldwide, with most patients eventually progressing to...

Published: 8/27/2026 | Inventor(s): Neil Lin

Keywords(s):

Category(s): Therapeutics > Oncology, Software & Algorithms > Artificial Intelligence & Machine Learning, Life Science Research Tools > Research Methods

Harnessing Embryonic Factors to Modulate the Tumor Microenvironment and Bypass Therapeutic Resistance (UCLA Case No. 2026-099, Kitai Kim)

Contact UCLA Technology Development Group (TDG) for more information on this technology.

Published: 8/27/2026 | Inventor(s): Kitai Kim

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Enhanced Therapeutic Effect of Armored CAR-T Cells for the Treatment of Glioblastoma (UCLA Case No. 2024-066)

UCLA researchers from the Department of Microbiology, Immunology, and Molecular Genetics have engineered chimeric antigen receptor (CAR)-T cells that co-express defined immunostimulatory cytokines to enhance therapeutic efficiency against glioblastoma (GBM). BACKGROUND: Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor...

Published: 7/20/2026 | Inventor(s): Yvonne Chen

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > CNS and Neurology

A Novel Chemical Modification of PROTACs (Proteolysis Targeting Chimeras) to Increase Selectivity in Hypoxic Environments (UCLA Case No. 2024-094)

UCLA researchers from the Department of Chemistry and Biochemistry have developed a novel chemical modification of PROTACs to increase their selectivity under hypoxic conditions. BACKGROUND: Proteolysis targeting chimeras (PROTACs) are molecules that induce targeted degradation of proteins by recruiting a ubiquitin ligase to a protein of interest...

Published: 7/20/2026 | Inventor(s): Stuart Conway

Keywords(s):

Category(s): Chemical > Synthesis, Therapeutics > Oncology

Targeted Protein Degradation in Cancer via Hypoxia-Activated PROTACs and Molecular Glues (UCLA Case No. 2024-095)

UCLA researchers from the Department of Molecular and Medical Pharmacology have developed a dual small-molecule platform for targeted protein degradation in cancer. By combining hypoxia-activated PROTACs with rationally designed molecular glues, this approach addresses key limitations in tumor selectivity. BACKGROUND: Despite major advances in cancer...

Published: 7/20/2026 | Inventor(s): Stuart Conway

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

UCHL1 Inhibitors, Modifications, and Uses Thereof (UCLA Case No. 2026-123)

UCLA researchers in the Department of Molecular & Medical Pharmacology and have developed novel, highly potent small-molecule inhibitors of UCHL1 that selectively suppress tumor growth and metastasis in aggressive cancers with favorable in vivo safety profiles. BACKGROUND: Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a dual-function enzyme...

Published: 7/20/2026 | Inventor(s): Tanya Stoyanova, Michael Jung

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Oncology > Oncology (Small Molecules)

Engineered Gamma Delta T-Cells and Methods of Making and Using Thereof (UCLA Case No. 2020-913)

UCLA researchers in the Department of Molecular Immunology & Molecular Genetics have developed gamma delta (gd) T cell receptor gene-modified immune cells derived from stem and progenitor cells that enable scalable, off-the-shelf allogeneic cell therapies with broad therapeutic potential. BACKGROUND: Cell-based immunotherapies have demonstrated...

Published: 8/13/2026 | Inventor(s): Lili Yang, Derek Lee, Tyler Halladay

Keywords(s):

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Life Science Research Tools > Cell Lines, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Hematology, Therapeutics > Autoimmune, Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Infectious Diseases

Gene-Modified Conventional Type 1 Dendritic Cells (UCLA Case No. 2026-093)

UCLA researchers in the Departments of Medicine and Pulmonary Disease have recently developed a novel approach for improving the long-term efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer. Anti-PD-1 immunotherapy is used for treatment despite...

Published: 7/20/2026 | Inventor(s): Bin Liu, Steven Dubinett

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Gene Therapy And Editing, Therapeutics > Vaccines

Microbial Regulation of Immune Tolerance and Risk for Cancer (UCLA Case No. 2026-153)

UCLA researchers in the Department of Integrative Biology and Physiology have identified a microbiome-driven signaling pathway that increases serotonin production and colorectal cancer (CRC) risk which may serve as a valuable therapeutic target for CRC. BACKGROUND: The gut microbiome plays a central role in regulating host physiology through interactions...

Published: 7/20/2026 | Inventor(s): Elaine Hsiao, Lewis Yu

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Gastroenterology, Therapeutics > Immunology And Immunotherapy, Diagnostic Markers > Cancer

Partial Transcription Factor Reprogramming to Rejuvenate Exhausted Tumor-Specific T Cells into Stem-Like Memory T Cells (UCLA Case No. 2024-240)

UCLA researchers from the Department of Surgery have developed a novel approach to partially reprogram exhausted tumor-infiltrating T cells into stem-like memory T cells capable of durable tumor elimination. BACKGROUND: Adoptive cell therapies, such as tumor-infiltrating lymphocyte (TIL) therapy involve isolating T cells from a patient’s tumor,...

Published: 7/20/2026 | Inventor(s): Tyler McCaw, Joseph Crompton

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Stem Cells And Regenerative Medicine, Life Science Research Tools > Research Methods

1 2 3 4 5 6 7 8 9 10 ...